It’s been a busy week in community pharmacy…
This week, we brought you the results of the 2018 UTS Pharmacy Barometer: we saw growth in community pharmacist wages; we found general confidence is up, but not amongst managers; we found that relationships between GPs and pharmacists are actually improving; and more pharmacy facts.
We heard disturbing stories from the Royal Commission into Aged Care Quality and Safety, where doctors were questioned over their decisions regarding risperidone. Meanwhile GPs continue to criticise the Queensland pharmacist prescribing trial.
In flu news, expert Professor Robert Booy said 2019 is so far a “really strange” year for the disease, and speculated on the reasons behind the early surge in cases; and in relation to the increase in flu as well as measles in the community, AHPRA issued advice to health professionals regarding the messages they send around public health initiatives like vaccination.
Palliative Care Australia released a position statement warning that palliative care patients are being placed at risk of harm as an unintended consequence of tighter restrictions around non-cancer opioid prescribing.
In business news, the ACCC said it wouldn’t oppose GSK’s proposed acquisition of Pfizer’s consumer healthcare business in Australia.
And in exciting news for AJP, our podcast is here, hosted by Carlene McMaugh. Click here for more information!